Purchase this article with an account.
S. Kotak, G. F. Schwartz, J. Mardekian, J. Fain; Incidence of Dry Eye or Ocular Infection in Open-Angle Glaucoma (OAG) and Ocular Hypertension (OH) Patients Treated With Latanoprost (LAT) With BAK or Travoprost-Z (TRAV-Z) With SofZiaTM. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2762.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the 1-year incidence rates of dry eye or ocular infections in OAG and OH patients newly treated with LAT or TRAV-Z.
Retrospective study of 3 US-based patient-centric medical/pharmacy claims databases (MedStat, Pharmetrics, i3-Ingenix) of patients with any OAG or OH diagnosis within 3 months of the first (index) prescription for LAT or TRAV-Z monotherapy. Excluded were those with a LAT or TRAV-Z prescription within 6 months pre-index or with a diagnosis of dry eye or ocular infection (ICD-9-CM codes 372.30, 372.39, 372.20, 372.00, 372.03, 372.53, 370, 370.0, 370.00, 370.2, 370.20, 370.21, 370.3, 370.33, 370.4, 370.8, 370.9, 375.15, 710.2; CPT: 68760, 68761) within 6 months pre-index. Time to incidence in the first year post-index was estimated with a composite endpoint: dry eye-related diagnosis or ocular infection by ICD-9-CM code OR prescription for RestasisTM or ocular antibiotics.
1208 patients were identified in MedStat (LAT, 980; TRAV-Z, 228). Over 1 year, 36.3% (356/980) of LAT and 38.6% (88/228) of TRAV-Z patients were identified with composite endpoint (P=0.4395; log-rank test). Similarly, 2766 patients were identified in Pharmetrics (LAT, 2177; TRAV-Z, 589). Over 1 year, 21.8% (474/2177) of LAT and 20.9% (123/589) of TRAV-Z patients were identified with composite endpoint (P=0.7611; log-rank test). Lastly, 1970 patients were identified in i3-Ingenix (LAT, 1164; TRAV-Z, 806). Over 1 year, 34.6% (403/1164) of LAT and 32.6% (263/806) of TRAV-Z patients were identified with composite endpoint (P=0.8794; log-rank test).
The retrospective analysis of 3 large prescription databases revealed that OAG and OH patients newly treated with BAK-containing LAT or SofZia-containing TRAV-Z did not differ statistically in rates of dry eye or ocular infections, as defined in the study, during the first year post-index. Limitations of claims-based analyses: nonrandomization; cannot account for over-the-counter use or samples.
This PDF is available to Subscribers Only